Kajian klinikal COPD di Colorado
15 kajian untuk COPD sedang mencari peserta di lokasi di Colorado.
Bandar di Colorado
Teks kajian rasmi (Bahasa Inggeris)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Aurora
- Research Site, Denver
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005, Boulder
- Critical Care Pulmonary & Sleep Associates- Site Number : 8400081, Lakewood
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Lynn Institute of Denver, Aurora
Mengambil pesertaFasa 2
Umur 40 hingga 85 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07684820A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- National Jewish Health Medical Center, Denver
Mengambil pesertaFasa 2
Umur 40 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07759245An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- UCHealth - Medical Center of the Rockies, Loveland
Mengambil peserta
Umur 40 hingga 80 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06035120Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- National Jewish Health, Denver
Mengambil pesertaFasa 2
Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07059091eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lakewood
Mengambil pesertaFasa 3
Umur 40 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07177339MoblO2 to Maintain Oxygenation
- National Jewish Health, Denver
Mengambil peserta
Umur 25 hingga 95 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07704567SPIROMICS Study of Early COPD Progression (SOURCE)
- National Jewish Health, Denver
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 30 hingga 55 · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05033990Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
Mengambil pesertaFasa 2
Umur 35 hingga 89 · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05937854Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
Mengambil peserta
Umur 40 ke atas · Semua jantina · Dikemas kini 8 Mei 2026 · NCT05896579Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
Mengambil peserta
Umur 40 ke atas · Semua jantina · Dikemas kini 8 Mei 2026 · NCT07576894Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Aurora
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06961214PiMZ Longitudinal Cohort (PiMZ Logic)
- National Jewish Health, Denver
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jan 2026 · NCT06505603PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
- University of Colorado, Denver
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Okt 2023 · NCT05306743Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.